Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio, the online open-access journal of the American Society for Microbiology (ASM.)
"This work sets the stage for additional animal studies to see if tamoxifen can be used as a drug in people and will allow us to design new drugs related to tamoxifen that are better antifungals," says Damian Krysan of the University of Rochester, an author on the study.
Cryptococcosis is one of the most prevalent human fungal infections, responsible for approximately 1 million new infections and 620,000 deaths worldwide each year. The disease strikes primarily people living with HIV/AIDS and causes more deaths in this population than tuberculosis. It manifests as either pneumonia or a brain infection known as meningoencephalitis.
"The gold standard therapy for this infection is a combination of amphotericin B and 5-flucytosine. These drugs were first used in the late 1950s when penicillin was the antibiotic of choice. There have been no substantial improvements in the treatment of this disease in a half-century and the therapy is not available in many regions of the world that need it most," says Krysan.
In areas of the world where the gold-standard therapy is not available, like sub-Saharan Africa, the drug of choice is fluconazole because it is widely available and inexpensive. Unfortunately, it is much less effective since it does not actually kill the fungus.
"Recently, interest in re-using old drugs to treat new diseases has increased as a way to develop new therapies more quickly. We screened a large collection of old drugs for drugs that kill Cryptococcus and rediscovered tamoxifen," says Krysan. "We used clinical microbiology tests to determine whether the molecules had promising activity against Cryptococcus both alone and in combination with other antifungal drugs such as fluconazole. The combination of tamoxifen and fluconazole was synergistic; this means that the combination is more than 4-times more active than either alone."
Krysan and his colleagues also demonstrated that tamoxifen does not kill the fungus in the same way it works against breast cancer. Instead, it inhibits proteins related to calmodulin, an important calcium binding protein. They found that by making modifications to tamoxifen that improve its ability to interfere with calmodulin, they also improved its ability to kill Cryptococcus.
"An effective, widely available treatment for cryptococcal meningitis is an unmet clinical need of global importance," says Krysan. "These results indicate that tamoxifen is a pharmacologically attractive scaffold for the development of new anti-cryptococcal drugs and provide a mechanistic base for its further optimization."
Explore further: Combo therapy helps knock out fungal meningitis
Medical Xpress on facebook
Related Stories
Breast cancer drug shows promise against serious infections
Jul 20, 2009
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. ...
Combo therapy helps knock out fungal meningitis
Apr 03, 2013
(HealthDay)— A drug regimen containing two powerful antifungal medicines—amphotericin B and flucytosine—reduced the risk of dying from cryptococcal meningitis by 40 percent compared to treatment with ...
First in-human trial of endoxifen shows promise as breast cancer treatment
Dec 12, 2013
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate ...
Study confirms long term benefits of tamoxifen
Jun 03, 2013
(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference. ...
New study finds titan cells protect Cryptococcus
May 28, 2012
Giant cells called "titan cells" protect the fungus Cryptococcus neoformans during infection, according to two University of Minnesota researchers. Kirsten Nielsen, Ph.D., an assistant professor in the department of microb ...
Recommended for you
EU rules are denying children latest cancer drugs
7 hours ago
Children with cancer are being denied new, potentially life-saving drugs, because EU rules are allowing companies to trial some drugs only in adults, leading cancer experts warn today.
Study uncovers possible genetic markers in breast cancer that spreads to the brain
7 hours ago
The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE.
ASTRO and SSO issue consensus guideline on margins for breast-conserving surgery with WBI
8 hours ago
The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast ...
President's panel calls for more girls, boys to get HPV vaccine
8 hours ago
(HealthDay)—Too few American girls and boys are getting vaccinated against the cancer-causing human papillomavirus (HPV), the President's Cancer Panel reported Monday.
Study identifies a key cellular pathway in prostate cancer
9 hours ago
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...
Weakness exposed in most common cancer gene
11 hours ago
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies ...
User comments
© Medical Xpress 2011-2014, Science X network
Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio, the online open-access journal of the American Society for Microbiology (ASM.)
"This work sets the stage for additional animal studies to see if tamoxifen can be used as a drug in people and will allow us to design new drugs related to tamoxifen that are better antifungals," says Damian Krysan of the University of Rochester, an author on the study.
Cryptococcosis is one of the most prevalent human fungal infections, responsible for approximately 1 million new infections and 620,000 deaths worldwide each year. The disease strikes primarily people living with HIV/AIDS and causes more deaths in this population than tuberculosis. It manifests as either pneumonia or a brain infection known as meningoencephalitis.
"The gold standard therapy for this infection is a combination of amphotericin B and 5-flucytosine. These drugs were first used in the late 1950s when penicillin was the antibiotic of choice. There have been no substantial improvements in the treatment of this disease in a half-century and the therapy is not available in many regions of the world that need it most," says Krysan.
In areas of the world where the gold-standard therapy is not available, like sub-Saharan Africa, the drug of choice is fluconazole because it is widely available and inexpensive. Unfortunately, it is much less effective since it does not actually kill the fungus.
"Recently, interest in re-using old drugs to treat new diseases has increased as a way to develop new therapies more quickly. We screened a large collection of old drugs for drugs that kill Cryptococcus and rediscovered tamoxifen," says Krysan. "We used clinical microbiology tests to determine whether the molecules had promising activity against Cryptococcus both alone and in combination with other antifungal drugs such as fluconazole. The combination of tamoxifen and fluconazole was synergistic; this means that the combination is more than 4-times more active than either alone."
Krysan and his colleagues also demonstrated that tamoxifen does not kill the fungus in the same way it works against breast cancer. Instead, it inhibits proteins related to calmodulin, an important calcium binding protein. They found that by making modifications to tamoxifen that improve its ability to interfere with calmodulin, they also improved its ability to kill Cryptococcus.
"An effective, widely available treatment for cryptococcal meningitis is an unmet clinical need of global importance," says Krysan. "These results indicate that tamoxifen is a pharmacologically attractive scaffold for the development of new anti-cryptococcal drugs and provide a mechanistic base for its further optimization."
Explore further: Combo therapy helps knock out fungal meningitis
Medical Xpress on facebook
Related Stories
Breast cancer drug shows promise against serious infections
Jul 20, 2009
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. ...
Combo therapy helps knock out fungal meningitis
Apr 03, 2013
(HealthDay)— A drug regimen containing two powerful antifungal medicines—amphotericin B and flucytosine—reduced the risk of dying from cryptococcal meningitis by 40 percent compared to treatment with ...
First in-human trial of endoxifen shows promise as breast cancer treatment
Dec 12, 2013
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate ...
Study confirms long term benefits of tamoxifen
Jun 03, 2013
(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference. ...
New study finds titan cells protect Cryptococcus
May 28, 2012
Giant cells called "titan cells" protect the fungus Cryptococcus neoformans during infection, according to two University of Minnesota researchers. Kirsten Nielsen, Ph.D., an assistant professor in the department of microb ...
Recommended for you
EU rules are denying children latest cancer drugs
7 hours ago
Children with cancer are being denied new, potentially life-saving drugs, because EU rules are allowing companies to trial some drugs only in adults, leading cancer experts warn today.
Study uncovers possible genetic markers in breast cancer that spreads to the brain
7 hours ago
The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE.
ASTRO and SSO issue consensus guideline on margins for breast-conserving surgery with WBI
8 hours ago
The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast ...
President's panel calls for more girls, boys to get HPV vaccine
8 hours ago
(HealthDay)—Too few American girls and boys are getting vaccinated against the cancer-causing human papillomavirus (HPV), the President's Cancer Panel reported Monday.
Study identifies a key cellular pathway in prostate cancer
9 hours ago
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...
Weakness exposed in most common cancer gene
11 hours ago
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment